As of 2026-01-17, the Intrinsic Value of Abbott Laboratories (ABT) is 146.44 USD. This Abbott valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 121.76 USD, the upside of Abbott Laboratories is 20.30%.
The range of the Intrinsic Value is 97.95 - 300.61 USD
Based on its market price of 121.76 USD and our intrinsic valuation, Abbott Laboratories (ABT) is undervalued by 20.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 97.95 - 300.61 | 146.44 | 20.3% |
| DCF (Growth 10y) | 117.53 - 335.93 | 170.11 | 39.7% |
| DCF (EBITDA 5y) | 109.26 - 141.61 | 121.04 | -0.6% |
| DCF (EBITDA 10y) | 126.43 - 169.77 | 143.02 | 17.5% |
| Fair Value | 200.95 - 200.95 | 200.95 | 65.04% |
| P/E | 127.58 - 331.49 | 218.42 | 79.4% |
| EV/EBITDA | 108.19 - 145.27 | 123.86 | 1.7% |
| EPV | 59.12 - 76.34 | 67.73 | -44.4% |
| DDM - Stable | 94.26 - 362.42 | 228.34 | 87.5% |
| DDM - Multi | 80.62 - 233.52 | 118.98 | -2.3% |
| Market Cap (mil) | 211,724.81 |
| Beta | 0.36 |
| Outstanding shares (mil) | 1,738.87 |
| Enterprise Value (mil) | 217,154.81 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.98% |
| Cost of Debt | 4.25% |
| WACC | 7.71% |